Amyotrophic lateral sclerosis & frontotemporal degeneration

Serum NfL, but not GFAP, differentiates primary lateral sclerosis from adrenomyeloneuropathy and hereditary spastic paraplegia type 4.

Pub Date : 2025-09-17 DOI: 10.1080/21678421.2025.2557936 Christoph Kessler, Carlo Wilke, Holger Hengel, Tim W Rattay, Aleksandra Maleska Maceski, Jens Kuhle, Ludger Schöls, Rebecca Schüle

Examining IGFBP7 as a potential therapeutic target in people with ALS.

Pub Date : 2025-09-13 DOI: 10.1080/21678421.2025.2559441 Andrew Brown, Colin Stubberfield, Fernando Vieira, Richard Bedlack

Dextromethorphan/quinidine (DMQ) for reducing bulbar symptoms in amyotrophic lateral sclerosis - assessment of treatment experience in a multicenter study.

Pub Date : 2025-09-11 DOI: 10.1080/21678421.2025.2557932 Susanne Spittel, Torsten Grehl, Patrick Weydt, Dagmar Kettemann, Rachel Fabian, Annekathrin Rödiger, Uta Smesny, Robert Steinbach, Benjamin Ilse, Ute Weyen, Susanne Petri, Rea Lumi, Bogdan Bjelica, Paul Lingor, Julian Grosskreutz, Bettina M Göricke, Waltraud Pfeilschifter, Wibke Schmeja, Johannes Dorst, Alexander Mensch, Jürgen Siebert, Jenny Norden, Sarah Bernsen, Senthil Kumar Subramanian, Barbara Hildebrandt, Bertram Walter, Christoph Münch, André Maier, Thomas Meyer